The latest development shows that BIOSECURE Act is gaining momentum in the US Congress and off Capitol Hill. In the meanwhile, the Chinese biotech sector embraces uncertainty but hopes that common interests in health innovation will prevail in the end.
As the BIOSECURE Act picks up momentum in the US Congress, the Chinese biotech community is emphasizing its support for innovation even as the legislation threatens to upend many of their operations in America.
In the latest demonstration of the strength behind the pending legislation, the Biotechnology Innovation Organization (BIO) has reversed positions on the bill and is severing the membership of WuXi AppTec, a “biotechnology company of concern” identified in the legislation
The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.
England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.
Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.
